Category: Biolase Technology Inc.Syndicate content

Vascular Dynamics reports raising $10 million in funding round | Medtech funding for the week of November 10, 2014

November 14, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Vascular Dynamics raises $10m; Spiracur raises $16m from GE Capital; Biolase lands $35m private placement; Monteris Medical raises $30m Series B round for NeuroBlate robotic brain tumor laser

Vascular Dynamics raises $10m

November 7, 2014 by Val Kennedy

Vascular Dynamics raises $10m

Biolase lands $35m private placement

November 11, 2014 by Val Kennedy

Dental laser maker Biolase lands a $35 million private placement with a group of investors that includes its chairman, chief executive officer and top stockholders.

Biolase lands $35m private placement

Dental laser maker Biolase (NSDQ:BIOL) said in landed a $35 million private placement with a group of investors that includes its chairman, CEO and top stockholders.

Bluegrass Vascular taps ex-ArthoCare R&D chief Niederauer for CEO | Personnel Moves

September 2, 2014 by Brad Perriello

Bluegrass Vascular Technologies taps former ArthroCare R&D chief Gabriele Niederauer to be its new president & CEO.

Bluegrass Vascular taps ex-ArthoCare R&D chief Niederauer for CEO | Personnel Moves

Bluegrass Vascular Technologies said it named Gabriele Niederauer its new president & CEO, hard on the heels of a Series A funding round that brought in $4.5 million for its Surfacer central venous catheter.

Medtronic CEO Ishrak seeks to reassure employees on MDT-COV deal | The week in medtech M&A

August 20, 2014 by MassDevice

Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Amid political noise, Ishrak seeks to reassure employees on Medtronic-Covidien deal; Will Medtronic follow Walgreen and abandon inversion in Covidien deal?; Medtronic founder Bakken backs Covidien buy; Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO; Allergan CFO Edwards steps down amid hostile Valeant takeover bid

Amid political noise, Ishrak seeks to reassure employees on Medtronic-Covidien deal

August 15, 2014 by Brad Perriello

Allergan CFO Edwards steps down amid hostile Valeant takeover bid | Personnel Moves

August 18, 2014 by Brad Perriello

Allergan CFO Jeff Edwards is stepping down amid a $44 billion hostile takeover bid from Valeant Pharmaceuticals and Pershing Square Capital Management.

Allergan CFO Edwards steps down amid hostile Valeant takeover bid | Personnel Moves

Allergan (NYSE:AGN) said today that longtime CFO Jeff Edwards is stepping down to honor a commitment he made to his family earlier this year, replaced by treasurer Jim Hindman effective immediately.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Biolase ex-CEO demands answers following his board resignation

August 14, 2014 by Arezu Sarvestani

Ousted CEO Federico Pignatelli turns the spotlight on new leadership at his former company after resigning from the board of directors.

Biolase ex-CEO demands answers following his resignation

Former Biolase (NSDQ:BIOL) CEO Federico Pignatelli isn't ready to put down his dukes after dropping his seat on the company's board of directors.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp